We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0TDD market cap is 288.15B. The company's latest EPS is DKK 29.7900 and P/E is 2.48.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 126.95B | 140.8B | 176.95B | 232.26B | 290.4B |
| Operating Income | 54.28B | 58.62B | 74.62B | 102.66B | 128.32B |
| Net Income | 42.14B | 47.76B | 55.53B | 83.68B | 100.99B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 144.92B | 194.51B | 241.26B | 314.49B | 465.8B |
| Total Liabilities | 81.6B | 123.76B | 157.77B | 207.93B | 322.31B |
| Total Equity | 63.33B | 70.75B | 83.49B | 106.56B | 143.49B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 51.95B | 55B | 78.89B | 108.91B | 120.97B |
| Investing | -22.44B | -31.61B | -24.92B | -43.89B | -128.9B |
| Financing | -32.24B | -25.49B | -51.8B | -63.16B | 8.74B |
| Market Cap | 288.15B |
| Price to Earnings Ratio | 2.48 |
| Price to Sales Ratio | 0.86 |
| Price to Cash Ratio | 15.98 |
| Price to Book Ratio | 1.74 |
| Dividend Yield | - |
| Shares Outstanding | 3.39B |
| Average Volume (1 week) | 30.11k |
| Average Volume (1 Month) | 40.79k |
| 52 Week Change | 249.15% |
| 52 Week High | 85.00 |
| 52 Week Low | 24.345 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Novo Nordisk A/s |
| Address |
novo alle bagsvaerd DK-2880 |
| Website | https://www.novonordisk.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
